Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19

Sponsor: ScandiBio Therapeutics AB

Collaborators: Istanbul Medipol University Hospital, Istanbul Umraniye Training and Research Hospital, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Bagcilar Training and Research Hospital, Kanuni Sultan Suleyman Training and Research Hospital, Alanya Alaaddin Keykubat University Alanya Training and Research Hospital, Canakkale 18 Mart University Health Research and Application Hospital

Purpose

To assess the clinical efficacy of the combination of metabolic cofactors supplementation (N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine) and hydroxychloroquine in COVID-19 patients.

Study Design

Open label, randomized, controlled, investigator-initiated, multi-center trial

Dose

L-Carnitine tartrate, 7.46 g/day plus N-Acetylcysteine, 5.1 g/day plus Nicotinamide riboside, 2 g/day plus Serine 24.7 g/day

Length of Intervention

14 days

Intrinsic Capacity

Vitality

Status

Recruiting

Condition or Disease 

COVID-19

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

COVID-19, ClinicalANAD StaffCOVID-19, Inflammation, Metabolic Health, Clinical Studies, Recruiting